Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
businesswire.com
news
2022-10-18 00:00:00

October 18, 2022 07:00 AM Eastern Daylight Time PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will not use its common stock to make the approximately $6.2 million interest payment due on December 1, 2022, as provided for under its Convertible Senior Secured Notes Indenture.

Under the terms of the agreement with bondholders, Acorda may elect to pay interest in cash or shares of the Company's common stock. Not paying in shares of common stock will ensure that there will be no dilution to shareholders.
